> 首页 > 产品 > 一抗 > 其他 > Anti-Arginase-1 / ARG1 Reference Antibody (Merck patent anti-Arginase-1)

Anti-Arginase-1 / ARG1 Reference Antibody (Merck patent anti-Arginase-1)

Anti-Arginase-1 / ARG1 Reference Antibody (Merck patent anti-Arginase-1) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-Arginase-1 / ARG1 Reference Antibody (Merck patent anti-Arginase-1) is 98.6%, determined by SEC-HPLC.
Immobilized PHA560 Human ARG1, His Tag at 2 µg/mL can bind Merck patent anti-Arginase-1, EC50= 0.005678 µg/mL.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P05089
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	34735 Da

Additional Information
Target/Specificity	Arginase-1 / ARG1
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.

Protein Information
Name	ARG1
Function	Key element of the urea cycle converting L-arginine to urea and L-ornithine, which is further metabolized into metabolites proline and polyamides that drive collagen synthesis and bioenergetic pathways critical for cell proliferation, respectively; the urea cycle takes place primarily in the liver and, to a lesser extent, in the kidneys.
Cellular Location	Cytoplasm. Cytoplasmic granule. Note=Localized in azurophil granules of neutrophils (PubMed:15546957)
Tissue Location	Within the immune system initially reported to be selectively expressed in granulocytes (polymorphonuclear leukocytes [PMNs]) (PubMed:15546957). Also detected in macrophages mycobacterial granulomas (PubMed:23749634). Expressed in group2 innate lymphoid cells (ILC2s) during lung disease (PubMed:27043409)

Research Areas

Application Protocols

Provided below are standard protocols that you may find useful for product applications.

Western Blot Protocol

Blocking Peptides Protocol

Dot Blot Protocol

Immunohistochemistry Protocol

Immunofluorescence Protocol

Immunoprecipitation Protocol

Flow Cytomety Protocol

Cell Culture Protocol